Ketamine for Treatment Resistant MDD

Open-label, single-group study evaluating repeated, individually tailored intramuscular or subcutaneous ketamine (0.3–1.5 mg/kg; up to 3×/week) in treatment-resistant major depressive disorder.

Primary aims are safety and tolerability; secondary assessments include antidepressant effectiveness, cognitive effects using the Neurotrax battery, and exploration of optimal dose, frequency and duration.